Orthocell’s (ASX:OCC) Remplir™ poised to revolutionise nerve repair surgery
December 2, 2024Orthocell (ASX:OCC) is on the cusp of redefining nerve repair surgery with its latest development, Remplir™, a collagen-based medical device for peripheral nerve reconstruction.
Having completed its pivotal U.S. FDA 510(k) regulatory study, Orthocell achieved all required endpoints, reinforcing the safety and efficacy of Remplir™.
This milestone marks a significant step toward entering the US$1.6 billion nerve repair market.
A Game-Changer in Nerve Regeneration
The study, conducted in collaboration with leading Australian researchers, evaluated the performance of Remplir™ using a sciatic nerve injury model in rats.
The results are groundbreaking:
- Motor and Sensory Recovery: By 12 weeks post-treatment, motor function and sensory response in the treated limbs were comparable to untreated limbs.
- Tissue Biocompatibility: No adverse tissue reactions such as inflammation or scarring were observed, crucial factors that can impede nerve regeneration.
- Superior Healing Environment: Remplir™ promoted a favourable macrophage response, transitioning inflammatory cells into a healing phenotype (M2), essential for tissue repair.
Professor Minghao Zheng of the University of Western Australia highlighted Remplir’s advantages, stating, “Use of Remplir™ did not induce inflammation or scarring… this outstanding local tissue response, combined with its optimal handling qualities, will be a key advantage for Remplir in nerve repair surgery.”
Aiming for Global Dominance
With approvals already secured in Australia, New Zealand, and Singapore, Orthocell is now focused on gaining U.S. FDA clearance, expected in Q1 CY25, followed by market entry.
The company is well-prepared, boasting a strong balance sheet of $33 million to drive commercialisation.
Orthocell CEO Paul Anderson remarked, “The study results validate the superior outcomes of Remplir™, providing key data for the FDA submission. We believe Remplir™ will redefine the nerve repair market and become an important element in the success of nerve repair surgery.”
Why It Matters
Peripheral nerve injuries, which often lead to debilitating conditions, typically require intricate surgical interventions; however, traditional methods, despite their effectiveness, are limited by challenges such as inflammation and scarring.
Remplir™ overcomes these obstacles by not only addressing these issues but also streamlining the surgical process, providing surgeons with a dependable tool for consistent and predictable outcomes.
The global nerve repair market is poised for growth, and with its innovative technology and strategic vision, Orthocell is positioned to capture significant market share.
The implications extend beyond healthcare economics, offering improved quality of life for patients with nerve injuries.
Looking Ahead
Orthocell’s next steps include expanding into key markets such as Canada, the EU, and South-East Asia while ensuring seamless commercialisation in the U.S.
Its robust pipeline and innovative approaches signal a promising future, making it a company to watch in the regenerative medicine space.
In a field often dominated by incremental advances, Orthocell’s Remplir™ represents a true leap forward—a compelling story of innovation meeting clinical need, backed by science and a clear strategy.
Please note the following valuable information before using this website.
Independent Research
Market Open Australia is intended to be used only for educational and informative purposes, and any information on this website should not be taken as investment advice or guidance. It is important to conduct your own research before making any investment decisions, which should be based on your own investment needs and personal circumstances. Any investment decisions based on information contained on this website should be taken in line with independent financial advice from a qualified professional or should be independently researched and verified.
